Advancing Sickle Cell Care Through Research and Real-World Data

The scientific understanding of sickle cell disease has advanced considerably over the past two decades. Genetic therapies have moved from theoretical possibility to clinical reality. New pharmacological agents have demonstrated meaningful reductions in crisis frequency. Screening programmes have expanded access to early diagnosis. Yet despite these advances, significant gaps remain between what research has established and what patients experience in daily life.

Closing those gaps requires combining the rigour of clinical research with the breadth and immediacy of real-world data.

The Limitations of Clinical Trials Alone

Clinical trials provide the strongest evidence for the safety and efficacy of new treatments. They are the foundation of evidence-based medicine. But clinical trials are also, by design, conducted under controlled conditions with selected patient populations. The patients who participate in trials may not fully represent the diversity of people living with sickle cell disease in the real world — in terms of age, genotype, comorbidities, access to healthcare, or socioeconomic context.

Real-world data complements clinical trials by capturing the experience of a broader patient population under ordinary conditions. It reflects the complexity that trials cannot always accommodate: the patient who is managing sickle cell disease alongside other chronic conditions, the patient in a region with limited specialist access, the patient whose disease course doesn't align neatly with trial eligibility criteria.

What Real-World Data Reveals

Large-scale analysis of real-world patient data has begun to reveal patterns that clinical trials alone could not identify. Research combining electronic health records, patient-reported outcomes, and continuous biometric monitoring has shed light on several important areas.

Trigger variability across populations: While certain triggers — cold temperatures, dehydration, physical overexertion, and infection — are well-established, real-world data reveals significant individual variation in trigger sensitivity. Understanding a patient's personal trigger profile is increasingly recognised as central to effective management.

Pre-crisis biometric patterns: Analysis of continuous monitoring data has identified consistent physiological signatures that precede vaso-occlusive crises in many patients. These signatures — involving combinations of heart rate, oxygen saturation, temperature, and activity data — appear hours before pain onset, offering a window for early intervention.

Treatment response variation: Real-world data has highlighted that patient responses to established treatments, including hydroxyurea, vary considerably. Understanding the factors associated with differential response may help clinicians personalise treatment selection more effectively.

The Path Forward

Advancing sickle cell care requires treating research and real-world evidence as complementary rather than competing. Clinical trials establish what is possible. Real-world data tells us how that potential is realised — or limited — in the full complexity of patients' lives.

As monitoring technology becomes more accessible and patient data becomes more consistently collected, the evidence base for sickle cell management will continue to deepen. The ambition is a future in which every patient's care plan is informed not only by population-level evidence but by the accumulated understanding of their own health history.